AMDL's Recent Israeli Patent for an Animal Model for the Evaluation of Vaccines Could Be Significant for Clinical Trials for Bio
May 17 2007 - 6:00AM
PR Newswire (US)
TUSTIN, Calif., May 17 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), developer and marketer of tests for the early detection
of cancer and other serious diseases, announced today that it has
received an important Israeli patent for an animal model for the
evaluation of vaccines, which is a part of its unique Combination
Immune Therapy (CIT) technology. CIT is a technology owned by AMDL
that may be useful in treating specific forms of cancer. AMDL also
has patents and patents pending claiming a novel model, and methods
of using these models, derived through the CIT technology it
believes will be far more useful than animal studies because AMDL's
"humanized" mice have human-like immune systems. "Medical science
has long been concerned about adverse occurrences in human trials
that aren't predicted in traditional animal studies," said Gary
Dreher, AMDL CEO. "With the novel animal models we have developed,
some of these important concerns could be eliminated." The
"humanized" mouse as claimed by AMDL has been engineered to possess
a human-like immune system. This "transgenic" mouse is extremely
useful for studying the potential therapeutic benefits of candidate
gene therapy compositions. Because the natural mouse immune system
differs from the human immune system, experiments conducted in
conventional mice are not always predictive of how new therapeutic
compounds will work in humans. However, transgenic mice made in
accordance with AMDL's patents have an immune system more like a
human's. Results obtained from experiments using this mouse may
correlate significantly better than traditional animal models. That
is why these mice are referred to as "humanized mice." CIT uses two
genes in combination to build the body's immune system and to
destroy cancer cells. The GM-CSF gene alters the tumor to activate
tumor-specific T-cells within the immune system, while the B7-2
gene enters the tumor to stimulate larger and stronger T-cells to
fight the cancer. This is a variation of the traditional concept of
gene therapy, which seeks to replace damaged or abnormal genes with
healthy ones. Replacing defective genes in cancer cells has proven
impractical because of the number of genes involved. CIT has
undergone successful Phase I clinical trials in skin and brain
cancer patients and was shown to be 100 percent effective in a
humanized mouse model at the University of Alberta, Canada.
Publications that have reported on this therapy include "Human Gene
Therapy" and "Neurosurgery." Currently AMDL holds patents for the
"humanized mouse" in the U.S., Australia and Singapore. "The major
pharmaceutical companies are searching for products in the
multi-billion dollar global cancer market and we believe that CIT
has significant, important features to offer to these firms," said
Gary Dreher, AMDL President and CEO. AMDL is seeking a strategic
partner for clinical trials, and eventual marketing, of CIT. About
AMDL: AMDL, Inc., headquartered in Tustin, California, with
operations in Shenzhen, Jiangxi and Jilin China, through its wholly
owned subsidiary Jade Pharmaceutical Inc. ("JPI" and or "Jade"), is
an international biopharma company. AMDL, together with Jade,
engages in the development, manufacture and marketing of
proprietary pharmaceutical and diagnostic products. More
information about AMDL and its products can be obtained at
http://www.amdl.com/. Jade has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiaries, Jade currently manufactures large volume
injection fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
Forward-Looking Statements: This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024